TNFRSF1B and cutaneous mastocytosis: In Cox’s multivariate analysis, patients aged>54 years, with tumors at clinical stages III or IV, non-superficial spreading, c.*922CT or TT genotypes, c.587TG or GG + c.*922CT or TT genotypes, and TATT haplotypes of TNFRSF1B SNVs had more chances of evolving to death due to CM (Table 3, Figure 1).